Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.
The FDA has approved label extensions for two of the most crucial cancer medications globally—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expanded indication now includes stomach c...
While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB’s bimekizumab, recently approved as Bi...
Find MoreIn recent years, the joint reconstruction devices market within the realm of orthopedics has undergone a profound evolution, owing to the technological advancements and innovations that have revolutionized treatment modalities and patient outcomes to a much greater extent. The intersection of innovative technologie...
Find MoreWithin a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication. The first approval on 30 October involves the reformulation of Voquezna to address Helicobacter pylori infection, followed by a second approval on 01 November for treating gastroesop...
Find MoreLung cancer is the leading cause of cancer death in both men and women around the world. It is expected that 127K people will die from this disease in the United States in 2023 (67K men and 60K women). NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. As per DelveInsight anal...
Find MoreRehabilitation equipment, a cornerstone in the realm of healthcare, has undergone a remarkable evolution over the years, propelled by the rising demand and their potential to improve patient outcomes and restore quality of life. From rudimentary tools and manual therapies to the present-day sophisticated, technolog...
Find MoreServier’s Tibsovo (ivosidenib tablets) has received an expanded indication from the FDA, allowing its utilization in patients diagnosed with relapsed or refractory myelodysplastic syndromes that exhibit an IDH1 mutation. This new approval represents the fifth for Tibsovo, which is already recognized for its efficac...
Find MoreRoche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO...
Find MoreThe Energy-Based Aesthetic Devices market stands at the forefront of the evolving landscape of cosmetic treatments, offering a comprehensive range of solutions for individuals seeking non-invasive and minimally invasive procedures to enhance their appearance. Over the past few years, intense advancements in technol...
Find MoreOn 27 October 2023, Coherus BioSciences and Shanghai Junshi Biosciences received FDA approval for Loqtorzi (toripalimab), marking a significant milestone as the first-ever sanctioned treatment for nasopharyngeal carcinoma. The medication has gained approval for use alongside cisplatin and gemcitabine as an initial ...
Find MoreMyocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....
Find MoreAcute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....
Find MoreRheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.